Since 2001, Aranesp® has provided innovative dosing options for precise titration and timely interventions to address Hb variability.1,2 But behind the product stands our experience, reliable supply, patient support and resources.
Convenience of less frequent dosing with QW and Q2W
intervals vs TIW dosing.
When Hb levels are unstable, timely
intervention is critical
for anemia management.1
Aranesp® is a proven option for patients
with anemia due to CKD.
*Cumulative estimate based on subjects who
received ≥ 1 dose (actual
completed and ongoing (per protocol
studies from launch
through October 31, 2016.
US exposure estimate methodology based on
total monthly dollar revenue,
revenue per patient, assumed patient loss rate,
route of administration share
from 2002 through November 30, 2017. It
assumes an increase on the patient level, not
accounting for dose increases,
and does not
reflect price increases since 2008.
Providing engaging anemia
and education for your patients
been a staple of
what we do.
Important Safety Information including Boxed WARNINGS